Aplastic Anemia
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study
The RACE study (NCT02009747) compared horse antithymocyte globulin antithymocyte globulin:
Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making
Morbidity and mortality in bone marrow failure bone marrow failure:
Fueling Your Journey: Nutrition Support for Aplastic Anemia, MDS, and PNH
Topic(s)
Aplastic Anemia
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this webinar, Sondos Khattab, Registered Dietitian, will discuss practical tips for managing treatment-related challenges, food safety, and making informed nutrition choices to support overall health. Questions can be submitted in advance at help@aamds.org.
Inherited Disorders
Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Presenter(s)
Sioban Keel, MD
Dr. Sioban Keel discusses inherited disorders, genetic testing, how these disorders are diagnosed, and their impact on treatment decisions and care.
Aplastic Anemia from the 2026 AAMDSIF Seattle Patient and Family Conference
Topic(s)
Aplastic Anemia
Presenter(s)
Sioban Keel, MD
Dr. Sioban Keel discusses the signs and symptoms of aplastic anemia, current diagnostic approaches, available treatment options, and the latest advances in patient care.
What is my diagnosis? From the 2026 AAMDSIF Patient and Family Conference
Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Bart Scott, MD
Dr. Bart Scott provides an overview of aplastic anemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and paroxysmal nocturnal hemoglobinuria (PNH). He explains the diagnostic tests and criteria used to make an accurate diagnosis.
OMISIRGE Fact Sheet
Omisirge is the first cellular therapy approved to treat patients with severe aplastic anemia. It is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood indicated for the…
Omidubicel-onlv
Omisirge is the first cellular therapy approved to treat patients with severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in whic